May 31, 2013—The group that represents hospitals in the 340B drug discount program has asked the pharmaceutical manufacturer Amgen to withdraw its new requirement that all 340B purchases of the company’s drug Neulasta be made exclusively through specialty distribution channels.
In a May 30 statement, Safety Net Hospitals for Pharmaceutical Access (SNHPA) said the policy discriminates against 340B hospitals in violation of federal guidelines and will impose significant financial costs and administrative burdens upon them.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)